|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among the ERG overexpressing cases (n = 54), higher expression levels were found in 92.3% of GS ≥8 tumors (P = 0.02).
|
25939480 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We find that prostate cancer specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor PTEN.
|
19396168 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa.
|
30191621 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Men whose tumors had high VDR expression had significantly lower prostate-specific antigen (PSA) at diagnosis (P for trend < .001), lower Gleason score (P for trend < .001), and less advanced tumor stage (P for trend < .001) and were more likely to have tumors harboring the TMPRSS2:ERG fusion (P for trend = .009).
|
21537045 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PSA testing, six-core biopsy, genetic counselling and mutation analysis for French Canadian founder mutations in the BRCA1 and BRCA2 genes, histopathological review of tumour tissue from family members, examination of loss of heterozygosity at the BRCA2 gene locus, immunohistochemistry to determine the expression of the ERG nuclear oncoprotein in prostate tumours, genotyping with eight selected risk-associated single nucleotide polymorphisms, Doppler ultrasonography of the leg, CT of the abdomen and pelvis with intravenous and oral contrast, chest CT with intravenous contrast for the assessment of metastatic prostate cancer, genetic testing for the G84E variant in the HOXB13 gene.
|
23318356 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High LIG4 expression was also tightly related to early biochemical recurrence when all tumors (P<0.0001) or the subsets of ERG-negative (P=0.0004) or ERG-positive prostate cancers (P=0.006) were analyzed.
|
26134445 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on an initial observation that CIC-DUX4-positive tumors show nuclear immunoreactivity for WT1 and ETS transcription factors, FLI1 and ERG, we performed a detailed immunohistochemical and molecular analysis including these markers, to further investigate the relationship between CIC-DUX4 tumors and ES.
|
24723486 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our findings established that Ets2 is a tumor suppressor gene in prostate cancer, and its loss along with other genes within the TMPRSS2-ERG interstitial region contributes to disease progression.
|
26880803 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
|
31745645 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A comparison with other molecular tumor features available from earlier studies revealed that TMPRSS2-ERG fusion as well as deletion of PTEN, 5q21, 6q15, and 3p13 was less frequent in IDH1-mutated than in non-mutated cancer.
|
29427004 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The loss of PSP94 expression was inversely correlated to EZH2 expression (<i>P</i> < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( <i>P</i> <0.0001 each).
|
31516752 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTEN loss was enriched among ERG-positive compared to ERG-negative tumors in both groups of patients.
|
28186998 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
None of 29 cases of BPH and 8 cases of normal zone of tumor tissue showed TMPRSS2-ERG fusion.
|
26424596 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The pair miR-145/ERG showed an exclusive staining for miR-145 in the nuclei of stromal cells, both in tumor and normal tissue, and for ERG in the cytoplasm with/without co-expression in the nucleus of tumor cells.
|
31186527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We used multicolor fluorescence in situ hybridization to show that CRPC CTCs, metastases, and prostate tissue invariably had the same ERG gene status as therapy-naive tumors (n=31).
|
19339269 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DNA index assessment revealed that the majority of tumors with CNI of TMPRSS2-ERG had generalized aneuploidy/tetraploidy in contrast to tumors without TMPRSS2-ERG CNI, which were predominantly diploid.
|
19190343 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PCA3 and TMPRSS2-ERG are commonly overexpressed biomarkers in prostate cancer, but reports have emerged demonstrating altered expression also in areas outside the tumour foci in cancerous prostates.
|
26294063 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental data suggest that heightened AR activity facilitates formation of TMPRSS2:ERG, a gene fusion present in approximately 50% of tumors of patients with prostate cancer.
|
24925673 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of whole blood mRNA for T1:E4 translocation in TMPRSS2:ERG was consistent with that in the tumour in 8/9 evaluable cases (one was concordantly positive, seven were concordantly negative), SPINK1 results were concordant in 9/10 cases (two were concordantly positive, seven were concordantly negative [P = 0.047 for the predictive value]).
|
22313860 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Of 305 tumor foci, 103 (34%) showed ERG rearrangement by FISH.
|
21773753 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ERPs unique for ERG (+) tumors reveal enrichment for cell growth and survival pathways while proteasome and redox function pathways were enriched in ERPs unique for ERG (-) tumors.
|
24115221 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On multivariate analysis, m-ERG(+) tumors were associated with lower preoperative serum prostate-specific antigen and Gleason scores, but greater extraprostatic extension (p<0.001). m-ETS(+) tumors were associated with seminal vesicle invasion (p=0.01), while m-SPINK1(+)/triple negative tumors had higher Gleason scores and were more frequent in Black/African American patients (p<0.001).
|
25964175 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The ERG promoter is marked by repressive chromatin marks mediated by polycomb proteins in both normal prostate cells and prostate cancer cells, which may explain ERG's predisposition to DNA methylation and the fact that tumors with ERG DNA methylation were more methylated, in general.
|
21946329 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein we report that in a large and diverse cohort of prostate carcinoma samples, miR-221 is down-regulated in patients with tumours bearing TMPRSS2:ERG fusion transcripts, thus providing a link between miRNA and gene fusion expression.
|
21378318 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SMCs are greatly depleted in advanced PB-MYC tumors and locally reduced in ERG/PTEN prostates, whereas in TRAMP tumors the SMC layers are increased.
|
27935821 |
2017 |